Connexin43 prevents and reverts resistance to BRAF/MEK inhibitors in cancers driven by BRAF mutations by selective elimination of therapy-induced senescent cancer cells

Área / Centro

Instituto de Investigación Biomédica de A Coruña (INIBIC)

Ponente

María Dolores Mayán

Lugar

Aula de Investigación "Maxi Lozano" (planta ‐7ª dcha.)

Fechas/Horario

12 de marzo

10:00h.